Armistice Capital, LLC Clovis Oncology, Inc. Transaction History

Armistice Capital, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	BUY	$4.13 - $6.41 $1.69 Million - $2.62 Million	408,000 Added 22.08%	2,256,000 $10.8 Million
Q3 2020 Nov 16, 2020	BUY	$4.82 - $7.72 $1.2 Million - $1.91 Million	248,000 Added 15.5%	1,848,000 $10.8 Million
Q2 2020 Aug 14, 2020	SELL	$5.69 - $9.69 $2.85 Million - $4.85 Million	-500,000 Reduced 23.81%	1,600,000 $10.8 Million
Q1 2019 May 15, 2019	SELL	$17.66 - $30.28 $51.8 Million - $88.9 Million	-2,936,000 Reduced 58.3%	2,100,000 $52.1 Million
Q4 2018 Feb 14, 2019	BUY	$11.63 - $32.67 $39.5 Million - $111 Million	3,400,000 Added 207.82%	5,036,000 $90.4 Million
Q3 2018 Nov 14, 2018	BUY	$29.37 - $49.48 $29.7 Million - $50.1 Million	1,012,000 Added 162.18%	1,636,000 $48 Million
Q2 2018 Aug 14, 2018	BUY	$42.06 - $62.4 $6.56 Million - $9.73 Million	156,000 Added 33.33%	624,000 $28.4 Million
Q1 2018 May 15, 2018	BUY	$50.12 - $67.72 $23.5 Million - $31.7 Million	468,000 New	468,000 $24.7 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Armistice Capital, LLC with notifications on news.